MAP2K7 and acute myeloid leukemia: To determine whether the phosphorylation of MEK/ERK cascade was indispensible for dasatinib-induced AML differentiation, HL60 and NB4 cells were treated with dasatinib in the presence of MEK inhibitor PD98059 and then analyzed for CD11b expression.